Objective methods to monitor statin adherence are needed. We have established a liquid chromatography-tandem mass spectrometry assay for quantification of atorvastatin and its metabolites in blood. This study aimed to develop an objective drug exposure variable with cut-off values to discriminate among adherence, partial adherence and nonadherence to atorvastatin therapy in patients with coronary heart disease.
| INTRODUCTION
Poor adherence to statin treatment is a prevalent challenge in cardiovascular disease prevention, 1-3 associated with adverse outcomes. [4] [5] [6] Regular assessment of adherence is recommended by the European lipid guideline from 2016, 7 and was recently given a class IA recommendation in the corresponding US guideline. 8 Adherence has traditionally been monitored by indirect methods such as clinical judgement, self-reports or pill counts, methods that are prone to misinterpretation and overestimation of actual intake. 9 Prescription fill rates obtained from pharmacy registries provides the most comprehensive data on statin adherence today. 9, 10 However, registry data is not feasible for documentation of statin intake in the individual patient. For statins, low-density lipoprotein cholesterol is an objective marker that might be used to monitor adherence. However, lowdensity lipoprotein cholesterol reduction secondary to statin therapy has been shown to vary from 5 to 70% between persons across all statin classes and doses. 11 Hence, objective methods to detect reduced adherence are requested 12 for the determination of true statin adherence in clinical practice.
Measurements of the active drug and/or its metabolites or directly observed therapy (DOT) are examples of objective methods for the assessment of drug adherence. 9 Assays for measuring statins and metabolites in blood with direct chromatography and tandem mass spectrometry (LC-MS/MS) methods have been described. [13] [14] [15] [16] [17] However, they are generally designed for studies on pharmacokinetics and bioequivalence. [13] [14] [15] [16] [17] We have recently reported a fast and reliable assay for the quantification of atorvastatin and its 5 major metabolites with LC-MS/MS methodology. 18 Importantly, this assay is feasible for the routine clinical laboratory with respect to technical implementation and interpretation of adherence. 18 Atorvastatin is the most frequently used statin for the prevention of coronary heart disease (CHD) in Europe 19 and Norway. 20 Algorithms to allow discrimination among complete adherence, partial adherence and nonadherence to atorvastatin treatment, assessed by objective methods, have not yet been developed. Such algorithms may allow identification of patients at-risk of future treatment discontinuation and thus in need of closer follow-up. To be able to monitor adherence, a drug exposure variable with strong correlation to the ingested dose is required. Atorvastatin is converted to hydroxyl and lactone metabolites in vivo. CYP3A4 is primarily responsible for the hydroxylations 21 and the enzyme activity shows high variability between individuals. 22 Accordingly, the variability of atorvastatin metabolism needs to be levelled out in the context of a reliable drug exposure variable. The sum of atorvastatin and its major primary metabolites accounts for the major pharmacokinetic variability of this drug. 23 We aimed to develop an objective drug exposure variable, reflecting the administered atorvastatin dose, with the ability to discriminate among adherence, partial adherence and nonadherence to atorvastatin therapy in CHD patients. We hypothesized, based on the reported half-life of atorvastatin in blood, 23 that adherence could be discriminated from partial adherence after the dose had been omitted for 1 to 3 days.
| METHODS

| Design and patient characteristics
Twenty-five adult CHD patients treated with atorvastatin 10 mg (n = 5), 20 mg (n = 6), 40 mg (n = 7) and 80 mg (n = 7) were included in a clinical pharmacokinetic adherence study conducted from January to February 2018. Patients were recruited from the outpatient clinic at Drammen Hospital, Norway. A prerequisite for participation was no CHD events for 2 years prior to study participation and no present symptoms of unstable CHD. The exclusion criteria were medical or technical complications of blood sampling and difficulties collaborating with the study protocol. Patients were consecutively assigned to either the test or control group. One patient who did not comply with the study protocol was excluded, leaving 24 patients eligible for the analyses. A study flow chart is shown in Figure S1 .
| Test procedure
Prior to inclusion, all patients participated in a 2-hour meeting with the study physicians where the background for the study and practical implementation was thoroughly explained. All patients were instructed to administer their atorvastatin dose between 7 and 10 AM once daily for at least 7 days prior to study start to ensure steady-state drug concentrations. On the first study day, all patients participated in a DOT study without having taken their morning dose. Blood samples were collected 1 hour before DOT (t −1 ) and immediately before DOT (t 0 ) to
What is already known about this subject
• Poor statin adherence remains a prevalent challenge in patients with coronary heart disease associated with adverse outcomes.
• Objective methods, feasible for use in clinical practice and future research, allowing detection of poor atorvastatin adherence in spot blood samples, have previously not been described.
What this study adds
• Suggested dose-normalized cut-off values allowing discrimination among adherence and partial adherence to atorvastatin treatment in patients with coronary heart disease. A cut-off value to identify nonadherent patients (>3 daily doses omitted) is also proposed.
• The proposed method may be used to identify patients at-risk of future statin discontinuation and promote communication about adherence and side-effects. In turn, this may improve lipid management. The methodological approach may also translate to other drugs administered in chronic diseases.
detect any unscheduled morning dose. Atorvastatin was then administered under observation by the study nurse and blood samples were collected 1 and 3 hours later in all patients. After the DOT study, half of the patients constituting the control group were not followed up further, whereas the test group, were instructed to stop taking atorvastatin and return for blood sampling after 24 (t 24 ), 48 (t 48 ), 72 (t 72 ) and 96 (t 96 ) hours. To provide data on drug and metabolite concentrations in patients with escape intake just prior to blood sampling, the test group also participated in a second DOT-study with blood sample collections 1 and 2 hours after atorvastatin administration (day 4, t 1 and t 2 ).
| Study assessments
| Assessment of atorvastatin and metabolites
Venous blood was sampled in EDTA vacutainers and handled according to both a low-temperature procedure and an ambient-temperature procedure as previously described. 18 The resulting plasma samples were analysed for the acid and lactone form of atorvastatin (parent drug), ortho-(2-OH) and para-(4-OH) hydroxyl atorvastatin with a 2-channel LC-MS/MS (Thermo Fisher Scientific, Waltham, MA, USA)
at Oslo University Hospital. We have previously reported that the preanalytical stability of the acid forms are acceptable for 1 week at ambient and cool temperature, while the lactone forms demonstrate acceptable preanalytical stability for 3 hours at cool temperature (2-8°C). 18 Due to the in-sample conversions of the lactone forms to acids, we examined the sums of acid and corresponding lactone as this ensures stability of the drug concentration when samples are kept in ambient temperature for 6 days. 18 Preset conditions for the alignment of optimal cut-off limits were: (i) to avoid that adherent patients are misclassified as partially adherent, a maximum of 1 day without drug intake was allowed; (ii) the cut-off between adherence and partial adherence aimed to indicate at least 2 days without drug intake; and (iii) the cut-off between partial and nonadherence aimed to indicate that >3 daily doses had been omitted.
The sum of parent drug and the metabolites were evaluated as test variables to differentiate among adherence and partial adherence. Additionally, we assessed ratios between the parent drug and individual metabolites to compare the ability to discriminate partial adherence.
The lower limit of detection is set by a signal-to-noise ratio at 3 for the analyte. Since the concentration related to this limit will vary between samples, methods and laboratories it is unsuitable as a standardized cut-off limit for nonadherence. Therefore, a concentration threshold set at approximately 3-fold the lower limit of detection was defined for each substance (metabolite). The instrument response (i.e. analyte/internal standard ratio) corresponding to these standardized concentration-based thresholds were investigated as potential discriminators between partial and nonadherence. The individual half-lives were calculated for the parent drug and each metabolite in the test group, assuming first order kinetics and using linear regression of the Ln-transformed concentrations against time at t 24 , t 48 , and t 72 .
All test group patients were then simulated on each dose level, and the time to reach the lower concentration threshold was estimated for each substance, using the slope and intercept of the equations obtained by linear regression. The discriminating performance of the nonadherence limits will depend both on the pharmacokinetic characteristics and the analytical sensitivity of the method for the individual substance. Accordingly, the metabolite with superior ability to separate nonadherence from partial adherence could be identified.
In order to explain potential large deviations in drug or metabolite concentrations, we analysed relevant sequence variants in the SLCO1B1(c521T > C), CYP3A4 (*22) and CYP3A5 (*3) genes using real-time polymerase chain reaction amplification with hybridization probes and melt curve analysis (LightCycler 480, Roche Applied Science, Penzberg, Germany). 
| Clinical data
| Ethics and safety
The study was conducted in accordance to the ethical principles of the Declaration of Helsinki and in consistence with ICH/Good Clinical Practice. The study protocol was reviewed by the Regional Committee for Medical and Health Research Ethics without remarks and approved by the local Data Protection Officer (16/00117-107). The Norwegian
Medicines Agency did not define the study as a clinical trial requiring approval since the main purpose was not to ascertain or verify/compare the efficacy or safety of atorvastatin. All patients gave a written informed consent to participate prior to study start.
| Statistical analysis
Statistical analyses were performed using SPSS version 25. The Student t test was applied to assess differences in means (standard deviation) between the control and test group for continuous variables.
The Fisher mid-P test was used for categorical variables. 24 All measurements of parent drug and metabolites were above the lower limit of quantification (LLOQ) when patients were adherent to dose before DOT and 24 hours after DOT. Fifteen percent of the measurements were below LLOQ when doses were omitted in the test group.
| The relationship between atorvastatin dose and exposure
Correlations between the different drug exposure variables and the atorvastatin dose are shown in Table 2 . There was a positive correlation between all individual analytes and the dose. The parent drug was numerically weaker correlated than the parent drug plus metabolites exposure.
| Factors associated with the drug exposure
Increasing age was associated with increasing dose-normalized trough 
| Identification of patients with partial adherence
When the test group had omitted tablet intake for 3 days, all the indi- Obtained with Spearman's correlation using t 0 samples handled according to the low temperature procedure. ATV, atorvastatin; 2OH, orthohydroxyl; 4OH, para-hydroxyl partial adherence when 2 or 3 doses were omitted, regardless of sample handling procedure (Table 3 ). Ratios between the acid plus lactone form of atorvastatin and 2-OH atorvastatin, as well as ratios between the acid plus lactone form of atorvastatin and 4-OH atorvastatin, discriminated less adequately between adherence and partial adherence (data not shown).
| Identification of nonadherence
The metabolite 2-OH atorvastatin acid (1-component), with instrument response corresponding to a standardized concentration threshold at 0.014 nmol/L, showed superior ability to distinguish nonadherence (omitting dose for >3 days) from partial adherence.
The time to reach this threshold, after cessation of drug intake, was There is no consensus with regards to the definition of adherence, partial adherence and nonadherence in the statin literature. 7, 9, 12 Indeed, this also applies for objective methods to monitor other cardiovascular drugs. Accordingly, the present methodological approach may also translate to determine the adherence to other drugs administered in chronic diseases. To our knowledge, only 1 previous study has applied an LC-MS/MS assay in clinical blood samples to determine adherence to atorvastatin. 25 A dichotomous classification of adherence based on atorvastatin blood concentration over or under the LLOQ was used. 25 Our adherence algorithm classifies adherence, partial adherence and nonadherence. With the chosen drug exposure variable and cutoff, partial adherence implies that the dose is omitted for up to 3 days.
| Identification of an unscheduled dose prior to blood sampling
A 6-component sum (dose-normalized atorvastatin acid plus all metabolites) <0.10 nM/mg provides 100% sensitivity and 92% specificity when 2 or 3 doses are omitted. Forty-two percent will be classified with partial adherence if a single dose is omitted (Figure 1 ). This cutoff was selected as a practical approach to minimize the risk of classifying adherent patients as partially adherent and to reduce the effect of a single apparent outlier in the data set. Standardized conditions for blood sampling are important to ensure the given diagnostic sensitivity and specificity. Thus, we recommend blood sampling just prior to the next scheduled dose, i.e. trough concentration.
We also present an alternative approach to classify partial adher- can be assumed for interacting drugs, not examined in the present study. Further studies will confirm the optimal method to distinguish adherence and partial adherence.
The categorization of nonadherence solely on the basis of nondetectable vs detectable drug levels in blood has important limitations with respect to standardization. In general, the lower limit of detection is below the quantitative range, and it is dependent on fac- The preanalytical procedures are simplified by using the sum of acid and lactone forms, allowing blood samples to be handled in ambient temperature. 18 In the present study, we demonstrate that the proposed cut-offs are equal for samples handled at ambient temperature, a major advantage for the potential use of the test in routine clinical practice. The 6-component sum correlated well with the administered dose at steady state, suggesting this would be a representative drug exposure variable with the benefit of levelling out within-and between-individual variations in drug metabolism. 22 Increasing age was associated with higher dose-normalized blood concentrations of both parent drug and metabolites, a finding supported by previous studies examining factors associated with variations in atorvastatin concentrations. 26, 27 Due to the limited sample size, we did not attempt to age adjust the drug exposure variable, but this should be considered in a larger cohort.
The recent emergence of new, expensive drugs targeting subclinical inflammation 28 and lowering lipids, 29 emphasizes the need to improve adherence to the cost-effective statins. Knowledge about the prevalence of execution issues (i.e. omitting doses) was strongly requested in a recent position paper from the European Society of Cardiology. 30 Our new direct method combined with the algorithms developed in the present study can be used in future studies to differentiate and describe the prevalence of adherence, partial adherence and nonadherence to atorvastatin therapy. When combined with clinical data, causes of partial and nonadherence to atorvastatin therapy may be revealed to develop new approaches for improving adherence.
Measurement of plasma drug levels revealed that nonadherence was common in patients with apparent treatment resistant hypertension in 2 recent studies. 31, 32 Data from a pilot study in patients with low or undetectable blood levels of blood pressure-lowering drugs indicated that confronting these patients with the study results, improved adherence and reduced average blood pressure with >15 mmHg. 33 Thus, a test for atorvastatin adherence may enhance the clinicians' awareness at follow-up visits and encourage communication about adherence between physician and patient.
| Limitations
Due to the limited sample size there is a risk of bias and spurious results when multiple-adjusted analyses are performed. Hence, patient factors besides age may be associated with variations in drug or metabolites exposure. The suggested cut-off values should therefore be validated, and potentially adjusted, in a larger data set including more patients with multiple comorbidities, interacting drugs and genetic variations that may influence the statin pharmacokinetics.
The present methodology should also be cross-validated with other adherence assessment methods. Patients with extremely high or low atorvastatin or metabolite concentrations could potentially be misclassified with the suggested algorithms. Further knowledge may guide the interpretation of the test when risk factors for misclassification are present. Even though we identified a cut-off that allows detection of escape dose intake 1 or 2 hours prior to blood sampling in a majority (i.e. 67 and 83%, respectively) of the partially adherent patients, the risk of white coat adherence is not eliminated. 9 Finally, concentrations below the LLOQ were used, although it brings along uncertainty. Achievement of a lower LLOQ should be addressed in future improvement of the methodology.
| CONCLUSION
Cut-off values based on the pharmacokinetics of atorvastatin and metabolites in spot blood samples, allowing discrimination among adherence, partial and nonadherence to atorvastatin therapy in CHD patients have been developed. The present direct method to determine atorvastatin adherence may optimize the use of cost-effective statins in clinical practice to improve lipid management and clinical outcomes.
